Clearly, more work needs to be done to better understand the impact of HMA treatment on the expression levels of oncogenes, since not all MDS patients examined by Liu et al. did demonstrate SALL4 upregulation in response to HMA therapy. This evidence concerns the gene SALL4 and myelodysplastic syndrome.